CN1326355A - 治疗肝素诱导的血小板减少症的方法 - Google Patents

治疗肝素诱导的血小板减少症的方法 Download PDF

Info

Publication number
CN1326355A
CN1326355A CN99813255A CN99813255A CN1326355A CN 1326355 A CN1326355 A CN 1326355A CN 99813255 A CN99813255 A CN 99813255A CN 99813255 A CN99813255 A CN 99813255A CN 1326355 A CN1326355 A CN 1326355A
Authority
CN
China
Prior art keywords
protein
heparin
activated protein
patient
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99813255A
Other languages
English (en)
Chinese (zh)
Inventor
C·J·菲舍尔
S·C·B·颜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1326355A publication Critical patent/CN1326355A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN99813255A 1998-11-13 1999-11-10 治疗肝素诱导的血小板减少症的方法 Pending CN1326355A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10843298P 1998-11-13 1998-11-13
US60/108,432 1998-11-13

Publications (1)

Publication Number Publication Date
CN1326355A true CN1326355A (zh) 2001-12-12

Family

ID=22322154

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99813255A Pending CN1326355A (zh) 1998-11-13 1999-11-10 治疗肝素诱导的血小板减少症的方法

Country Status (13)

Country Link
US (1) US6743426B2 (https=)
EP (1) EP1128842B1 (https=)
JP (1) JP2002529515A (https=)
CN (1) CN1326355A (https=)
AT (1) ATE320263T1 (https=)
AU (1) AU1477000A (https=)
BR (1) BR9915317A (https=)
CA (1) CA2351067A1 (https=)
DE (1) DE69930419T2 (https=)
ES (1) ES2259248T3 (https=)
IL (1) IL142255A0 (https=)
WO (1) WO2000029014A1 (https=)
ZA (1) ZA200102722B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468358B2 (en) * 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
CA2678587A1 (en) * 2007-02-28 2008-09-04 Paringenix, Inc. O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease
WO2009015183A1 (en) * 2007-07-23 2009-01-29 University Of Utah Research Foundation Method for blocking ligation of the receptor for advanced glycation end-products (rage)
CN104411316B (zh) 2012-05-09 2018-05-01 坎泰克斯制药股份有限公司 骨髓抑制的治疗
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
EP0591219B1 (en) 1991-01-11 2001-12-19 American Red Cross Expression of active human protein c in mammary tissue of transgenic animals
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
JPH05271098A (ja) * 1992-03-26 1993-10-19 Teijin Ltd 活性化プロテインｃを有効成分とする抗血小板剤
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
EP0872245B1 (en) * 1997-03-24 2006-03-08 Eli Lilly And Company Methods for treating vascular disorders with activated Protein C
CZ298429B6 (cs) * 1997-04-28 2007-10-03 Eli Lilly And Company Stabilní lyofilizovaný prostredek
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
US6743426B2 (en) 2004-06-01
ATE320263T1 (de) 2006-04-15
IL142255A0 (en) 2002-03-10
WO2000029014A1 (en) 2000-05-25
DE69930419T2 (de) 2006-09-07
EP1128842B1 (en) 2006-03-15
ES2259248T3 (es) 2006-09-16
CA2351067A1 (en) 2000-05-25
ZA200102722B (en) 2002-05-03
AU1477000A (en) 2000-06-05
DE69930419D1 (de) 2006-05-11
EP1128842A1 (en) 2001-09-05
BR9915317A (pt) 2001-08-07
JP2002529515A (ja) 2002-09-10
US20010018050A1 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
EP3395354B1 (en) Plasminogen for use in treating diabetic nephropathy
CN1235638C (zh) 活性蛋白c制剂
US4382083A (en) Therapeutic method for treating blood-clotting defects with factor VIIa
US4456591A (en) Therapeutic method for activating factor VII
CA3008185C (en) Method for prevention or treatment of acute and chronic thrombosis
EP3391902B1 (en) Plasminogen for use in the treatment of diabetic angiocardiopathy
US4479938A (en) Therapeutic composition containing factor VIIa
US6344197B2 (en) Methods for treating sepsis
JP7214245B2 (ja) 骨関節炎を予防または治療するための方法および薬剤
EP3556380A1 (en) Method for preventing and treating tissue and organ fibrosis
CN1326356A (zh) 治疗病毒性出血热的方法
CN1326355A (zh) 治疗肝素诱导的血小板减少症的方法
JP3805378B2 (ja) ｒＤＳＰＡα１の製造の方法
CN1326357A (zh) 治疗镰刀形红细胞贫血病及地中海贫血病的方法
JP2001518933A (ja) 血管障害の治療方法
CA3008186C (en) Novel method for preventing and treating angiocardiopathy
CN1329503A (zh) 治疗血小板减少性紫癜和溶血性尿毒综合征的方法
CA3046666C (en) Method for preventing and treating tissue and organ fibrosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication